Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

  1. Emelie Marklund
  2. Susannah Leach
  3. Hannes Axelsson
  4. Kristina Nyström
  5. Heléne Norder
  6. Mats Bemark
  7. Davide Angeletti
  8. Anna Lundgren
  9. Staffan Nilsson
  10. Lars-Magnus Andersson
  11. Aylin Yilmaz
  12. Magnus Lindh
  13. Jan-Åke Liljeqvist
  14. Magnus Gisslén

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1371/journal.pone.0241104
  2. ScreenIT

    SciScore for 10.1101/2020.07.11.20151324: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The study protocol was approved by the Swedish Ethical Review Authority
    Consent: (Registration number 2020-01771) and patients were included after written informed consent.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Seroconversion was defined as detectable levels of SARS-CoV-2-specific IgG antibodies in serum.
    SARS-CoV-2-specific IgG
    suggested: None
    Detection of SARS-CoV-2 specific serum antibodies: Serum-IgG antibodies against SARS-CoV-2 were analyzed using two commercially available serological assays: the qualitative Architect chemiluminescent microparticle immunoassay (Abbott Laboratories, USA), measuring IgG against SARS-CoV-2 N-protein, and the quantitative iFlash 1800 chemiluminescent immunoassay (YHLO, China), which measures IgG against both SARS-CoV-2 S- and N-proteins.
    SARS-CoV-2
    suggested: None
    N-protein
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Thereafter the serum/virus mixture was added to confluent Vero cells in 96 well microtiter plates with 175 µL MM and incubated at 37°C in a CO2 incubator.
    Vero
    suggested: None
    Software and Algorithms
    SentencesResources
    Detection of SARS-CoV-2 specific serum antibodies: Serum-IgG antibodies against SARS-CoV-2 were analyzed using two commercially available serological assays: the qualitative Architect chemiluminescent microparticle immunoassay (Abbott Laboratories, USA), measuring IgG against SARS-CoV-2 N-protein, and the quantitative iFlash 1800 chemiluminescent immunoassay (YHLO, China), which measures IgG against both SARS-CoV-2 S- and N-proteins.
    Abbott Laboratories
    suggested: None
    Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, Inc) and R 4.0.0.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    We acknowledge several limitations in this study. The number and timing of serum sampling differed between patients; detectable IgG may have occurred before sampling, meaning that the exact timing of seroconversion is uncertain. Also, a larger proportion of patients in the mild group than the severe group have been available for late follow-up sampling.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.07.11.20151324v1 on medRxiv